| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.4597 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.4710 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.4881 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.5175 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.5333 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.5413 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.5472 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.5546 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.5811 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.5837 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.6172 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.6534 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.6876 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.7328 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.7451 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.7815 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8090 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8113 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8138 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8167 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8219 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8239 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8281 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8284 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8291 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8327 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8329 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8468 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8571 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8586 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8595 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8648 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8666 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8698 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8759 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8763 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8801 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8811 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8825 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8879 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8890 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8942 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8948 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.8995 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9002 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9028 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9044 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9065 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9088 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9213 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9225 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9234 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9238 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9247 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9277 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9304 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9326 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9328 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9330 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9402 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9409 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9421 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9437 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9493 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9535 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9544 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9561 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9563 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9587 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9597 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9629 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9630 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9644 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9656 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9666 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9708 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9717 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9731 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9734 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9738 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9809 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9814 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9823 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9824 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9867 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9877 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9887 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9899 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9917 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9924 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9941 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9941 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 0.9998 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0000 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0002 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0021 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0058 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0110 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0128 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0157 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0172 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0185 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0188 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0194 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0203 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0241 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0264 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0275 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0279 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0317 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0337 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0342 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0355 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0370 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0376 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0399 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0415 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0434 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0468 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0474 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0496 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0498 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0505 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0540 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0556 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0566 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0610 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0621 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0646 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0668 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0724 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0742 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0794 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0820 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0823 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0839 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0844 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0875 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0900 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0928 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.0965 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1020 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1031 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1062 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1113 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1126 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1197 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1199 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1226 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1242 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1244 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1275 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1284 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1285 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1332 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1341 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1379 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1431 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1447 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1463 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1491 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1519 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1595 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1602 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1704 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1743 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1755 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1777 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1871 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.1919 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.2107 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.2121 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.2128 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.2165 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.2208 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.2299 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.2367 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.2459 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.2471 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.2607 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.2691 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.2752 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.2820 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.2859 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.3189 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.3807 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | N-acetylaspartate (NAA) | 1.4320 | scaled units | Placebo | +47HR POST INFUSION |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|